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The natumlly occurring sesquiterpene la&one ~apsi~r~n is a potent and selective inhibitor of SERCA ATPases, a family of Ca’+-piping 
ATPases present in the endoplasmic reticulum of all mammalian cells. We have studied some of the molecular features of thapsigargin responsible 
for its inhibitory action towards these Ca*’ ATPases. A series of thapsigargin analogues were synthesised and their inhibitory potencies determined 
using the uptake of “Ca*+ in bovine cerebellar microsomes as a sensitive marker of Ca*+ ATPase activity. An attenuation of the inhibitory potency 
relative to the parent compound was found ranging from slight to over 3 orders of magnitude. The inhibitory activity showed a very strong 
configuration dependence, a major contribution from the ester groups at C3 and ClO, and an apparently minor contribution from the lactone ring 
substituents. The data are consistent with thapsigargin fitting to a sterically discriminating cleft involving the hydrophobic transmembrane r gion 
of the ATPase, and is compatible with available kinetic evidence of thapsigar~n-rn~iat~ i~~tion. 
Thapsigargin; Ca”’ ATPase; Endoplasmic reticulum; Ca2’ store 
1. INTRODUCTION 
Correct distribution of Ca” ions within the cellular 
compartments is required for their well-established 
function as molecular signals in eukaryotic cells [1,2]. 
Endoplasmic reticulrmr (ER) (or its specialized do- 
mains) plays an impo~ant role in this compartment~i- 
zation [2,3]. ATP-dependent Ca2’ uptake from the cy- 
tosol to ER lumen is a prerequisite for rapid cytosolic 
signaling through receptor-mediated Ca” release [4], 
and for the role of ER-luminal Ca” in protein synthesis, 
maturation and sorting [5,6]. 
This ATP-requi~ng Ca” transport to the ER lumen 
is accomplished by a family of ER Ca2+ ATPases, 
termed SERCA ATPases [7]. Despite the wealth of in- 
formation accumulated about the molecular structure 
and function of these ion pumps (for recent reviews see 
[8,9]), important features of their operation require clar- 
ification. These include the precise location of catalytic 
Ca” binding sites, as well as the nature of the molecular 
rearrangements involved in the translocation of Ca2+ 
[lo]. Thapsigargin, a sesquiterpene lactone [I l] shown 
to selectively inhibit all of the SERCA isozymes with 
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subnanomolar potency [12] has in recent years provided 
new ways of studying the molecular function of ER 
Ca2+ ATPases. Upon binding, thapsigargin appears to 
induce a conformational state of the pump in which 
several of the partial reactions (e.g. Ca” binding, Ca2+- 
independent phosphorylation by Pi, nucleotide bind- 
ing), spanning rather distant domains of the ATPase, 
are blocked [13]. Thus, understanding of the molecular 
basis of the thapsigargin-ATPase interaction, including 
the location of the thapsigargin-binding site on the en- 
zyme, would contribute significantly to the major goal 
of elucidating its molecular operation. With this goal in 
mind, we have synthesized a number of thapsigar~n 
analogues and tested their ability to act as inhibitors of 
ER Ca2+ ATPase. 
2. MATERIALS AND METHODS 
Bovine cerebella were obtained from a local abbatoir, transported 
on ice and processed within 2-3 h of the animal’s death. All the 
subsequent preparation steps were also carried out on ice. Homogen- 
ization was carried out in a buffer (HB) containing; 20 mM TES, pH 
7.0; 300 mM sucrose; 0.1 mM phenyhnethylsulfonyl fluoride, by 
means of a loosely fitting pestle in a glass-teflon homogenizer, 6 
strokes at loo0 rpm. The material was then spun at 600 x g,, for 10 
min. The supernatant was spun again at lO,O@O x g,, for 10 min, and 
the resulting supernatant was centrifuged at 106,000 x g,, for 1 h. The 
pellet, resuspended in HB, constituted the microsomal fraction. It was 
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aliquoted and stored for several weeks at -80°C without loss of the 
ATP-dependent 45Ca2’ uptake activity. 
These compounds were synthesised as described in 1141. 
2.3. Measurement of the ATP-dependent “Ca’” uptake 
This was carried out at 37°C in 1 ml of a medium containing 
(concentrations in mM): TES, 20 (pH 7.0); KCl, 1 IO; MgCl,, 5; po- 
tasssium oxalate, 6; EGTA, 0.5; dsCaCIz (about 15,000 cpmfnmol), 
0.21 (resulting in 0.3 pM free Ca*‘), ATP 2; microsomaf protein 5Opg. 
Thapsigargin or its analogues in d~ethyls~lfo~de (DMSO) (or a 
corresponding amount of DMSO alone, final concentration 0.5% v/v) 
were added 12 min before starting the uptake by adding ATP in TES 
buffer (or an equivalent volume of TES for blank determinations). The 
incubations were stopped (after 10 min in routine experiments) by 
filtering the samples through Whatman GF/F filters (presoaked in 
polyethylene imine 0.1%) on a Brandell Harvester ~str~ent. The 
filters were immediately washed using an &-cold solution of Tris 20 
mM @H 7.0); MgCI, 10 mM; NaCll40 mM, and collected for scintil- 
lation counting at 100% efficiency. 
2.4, Calculations 
The ATPdependent component of 45Ca2+ uptake in the absence of 
any inhibitors was nommlized to 100%. The dos~e~ndent curves 
and inhibitor IC, values were obtained by fitting 4-parameters logistic 
equation to the data by means of the program GRAFIT (Erithacus 
Software Ltd.). Free Ca2* concentrations in the presence of EGTA, 
ATP and M$ were calculated by means of a computer bro8ram 
kindly provided by Prof. M. Gratzl, Ulm University. 
2.5. Other rne~ho~ 
Protein was determined by the fluorescamine method [15]. 
3. RESULTS 
The insert in Fig. 1 shows that in the presence of 
oxalate, the time-course of the “Ca2’ uptake due to the 
ER Ca” ATPase in cerebellar ~crosomes was linear 
for at least 30 min at low (0.3 PM) as well as high (10 
PM) concentrations of free Ca’+. (At 0.3 ,uM free Ca2+, 












.Ol 0.1 1 10 100 1000 
Inhibitor concentration nM 
Fig. 1. Dependence of the 4sCa2’ uptake in~bition in bovine cerebellar 
microsomes on the concentrations of various thapsigargin derivatives. 
Symbols indicate the individual drugs as follows: o, 1; A, 2; o, 3; 7, 
4; I, 5; l , 6; A, 7; v, 8; +, 9; x, 10. (See Fig. 2 for explanations of the 
drug numbers. Points are means of n independent determinations, 
with n values indicated in Fig. 2.) (Insert) Linear time-course of 4sCa2+ 
uptake under the conditions used for testing the inhibition due to 
thapsi~r~n derivatives. Abscissa: time in min. Ordinate: run01 45Ca2”/ 
mg protein. Free Car+ @M): o, 10, e,0.3. 
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microsome protein/assay tube; data not shown.) Fig. 2 
shows the inhibitors employed in this work, together 
with their respective IC& values derived from the dose- 
response curves of Fig. 1. For each of the inhibitors, the 
factor indicating its potency decrease relative to thapsi- 
gargin is also given as the RIc value. The inhibitory 
potencies of the thapsigargin derivatives were all 
smaller than that of the parent substance. This attenua- 
tion of the inhibitor potencies spanned a wide range, 
from barely significant o 3 orders of magnitude. Based 
on the Rlc values in Fig. 2, the compounds may be 
divided into three groups. Group I consists of com- 
pounds 1-4. Group II consists of compounds 5-8. 
Group III contains compounds 9 and 10. In group I, 
compounds 3 and 4 were obtained by acetylation of one 
of the OH groups on the lactone ring (at Cl 1 and C7, 
respectively). These changes resulted in small (less than 
3-fold) shifts of the inhibitory potency relative to thapsi- 
gargin. Isomerisation of the double bond of the angelic 
acid residue in 1 to give 2 did not afford any appreciable 
shift of the ICsO value. 
Compounds of group II showed moderate-to-strong 
shifts in the inhibitory potency. The strongest potency 
shifts in this group were observed with compounds 7 
(hydrolysis of acetate at CIO) and 8 (conversion of the 
angelic ester to a ketone at C3). In contrast, compounds 
5 and 6 represent an introduction of new groups: in 5, 
the angeloate at C3 was replaced by an octanoate, while 
in compound 6, both of the OH groups were acetylated. 
Introduction of these groups to obtain compounds 5 
and 6 resulted in a 3- to 6-fold smaller attenuation of 
ATPase inhibition than removing the ester groups at 
Cl0 or C3 (to obtain compounds 7 and 8). 
Group III consists of compounds 9 and 10, showing 
the largest potency shifts (over 400- and 3,000-fold, re- 
spectively) relative to thapsigargin. Compound 10 is a 
diastereoisomer of thapsigargin, in which the configura- 
tion at C8 has been inverted. Compound 9 is a diaster- 
eoisomer of 5, in which the confi~ation at C3 has been 
inverted. These inversions resulted in a trans disposal 
of the substituents at C3 and C8 in each of the com- 
pounds 9 and 10. 
4. DISCUSSION 
4.1. ATP-dependent 45Cd?c uptake as an expression of 
the ER-type (SERCA) Cd+-ATPuse activity in bo- 
vine cerebellar microsomes 
In the cerebellum, the SERCA 2b form of ER Ca2” 
ATPase appears strongly pr~o~nant [16,17], with the 
level of expression among the highest in the brain 
[17,18]. The high sensitivity of 4sCa2+ uptake assay, as 
used in the present work, was primarily due to two 
factors. Firstly, the non-specific (i.e. ATP-independent) 
45Ca2’ binding to the filters was only 5-10% of the total 
uptake. Secondly, addition of oxalate ion to the 4sCa2+ 
uptake medium allowed this uptake to proceed in a 
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Fig. 2. Thapsigargin derivatives and their inhibitory potencies. Drugs 
l-10 are defined as shown. IC,, values (nM) are means of n determi- 
nations, each based on fitting an independent set of points, with SEM 
(or range for n = 2) and n values indicated by numbers in the brackets. 
R, values were obtained by dividing the corresponding I& values 
by the IC,, value of unmodified thapsigargin (drug 1). 
linear fashion for at least 30 min (Fig. 1, insert), due to 
the precipitation of the 45Ca-oxalate complex in the 
lumen of ER vesicles stabilizing the intravesicular free 
45Ca2’ at a constant value [ 191. This enhancement of the 
uptake by oxalate occurs mainly in the ER-derived ves- 
icles [20], effectively diminishing the contribution of 
non-ER-type Ca2’ pumps (e.g. in plasma membrane 
vesicles oriented inside-out, or internal mitochondrial 
membranes) to the measured 45Ca2’ uptake. Fig. 1 
shows that the contribution of such non-ER-type Ca*+- 
ATPases was about l%, as indicated by that portion 
of uptake which could not be inhibited by thapsigargin 
or its analogues. 
4.2. Consequences of structural modzfkations of thapsi- 
gurgin for the inhibitory potency 
The molecular features of thapsigargin of potential 
importance for its interaction with Ca*‘-ATPases in- 
clude the lipoph~icity, the spatial confi~a~on, and the 
presence of substituents which provide sites of specific 
interactions with the protein. The lipophilic nature of 
thapsigargin implies that those portions of the enzyme 
located within the lipid bilayer might a priori be consid- 
ered a prime target for the drug. This possibility is 
indeed supported by the kinetic evidence. This evidence 
suggests that thapsigargin does not bind within the 
ATP-binding domain, located in the bulky, extra-mem- 
braneous portion of ATPase [ 13,211. On the other hand, 
thapsigargin was found to stabilize the transmembrane 
region of the ATPase 1223. These obse~ations, together 
with the binding stoichiometry of 1 mol thapsigarginl 
mol ATPase, are consistent with the possibility that a 
domain including amino acids from one or more of the 
ATPase transmembrane a-helices is responsible for thap- 
sigargin binding. The data to be discussed below would 
be consistent with such an ~tra-membraneously ocated 
domain being sterically constrained to form a ‘cleft’, 
discriminating between thapsigargin analogues of dif- 
ferent configurations. 
Until more definite information becomes available 
about the composition of this thapsigargin binding do- 
main, inte~retation of our present data in terms of 
specific drug-protein interactions must remain some- 
what tentative. With this caveat in mind, in the follow- 
ing we point out some structural features of thapsi- 
gargin which our data suggest o be of importance for 
its inhibitory activity, and which should aid attempts to 
define the excluded and essential volume [23] of the 
enzyme as a step towards the mapping of the binding 
site. 
The compounds of group I (2-4) showed only minor 
decreases of the inhibitory potency relative to the parent 
drug (1). The modest effects of aoetylation of the OH 
groups at the la&one ring in 3 and 4 would suggest hat 
this part of the molecule is only loosely involved in the 
binding to the ATPase. (This is further supported by a 
potent inhibition exerted by an analogue in which the 
carbonyl group at Cl2 has been reduced S.B. Chris- 
tensen and M. Treiman, unpublished). However, acetyl- 
ation of both hydroxy groups (compund 6, see below) 
affords a stronger reduction of the pump inhibitory 
activity than acetylation of any of these groups alone. 
This would suggest either that the presence of two ace- 
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tate groups makes this part of the molecule too volumi- 
nous, impeding its access to the binding cleft, or that the 
presence of a hydrogen donor at the lactone ring substit- 
uent(s) is of importance. 
Group II (58) consists of two types of compounds: 
those substituted with voluminous groups (5 and 6), and 
those in which acyl groups have been removed (7 and 
8). Replacement of the angeloyl group of thapsigargin 
with the vol~inous octanoyl group in 5 results in a 
lo-fold loss of the inhibitor potency, consistent with 
the idea that the angeloyl group binds within a sterically 
limited cleft. The aliphatic side chain extension might 
incur a steric disadvantage not compensated for by an 
increased potential for hydrophobic interactions. The 
considerable loss of i~ibito~ potency of 8 in which the 
angeloate group has been removed and replaced with a 
ketone group confirms that this part of thapsigargin 
might be intimately associated with the ATPase. Possi- 
ble interactions might include hydrogen bonding to the 
ester carbonyl group, interactions of the carbonyl group 
electrons with amino acid aromatic rings or hydropho- 
bic interactions. By analogy, the decreased inhibitory 
potency of 7 suggests that the acetate residue at Cl0 is 
of importance for the binding to the enzyme. 
The present data are not sufficient to separate une- 
quivocally the effects on the inhibitory potency due to 
the gross steric changes (for instance through a shape 
of the drug highly disadvantageous for the access to the 
binding cleft) from more subtle effects on specific inter- 
actions (for instance through weakening interactions 
between specific group(s) on the drug and the binding 
domain of the protein through misalignment). Thus 
both kinds of effects might contribute to the very pro- 
nounced potency shifts observed with the compounds 
in group III (9 and 10). Nevertheless, the severe reduc- 
tion in inhibitory potency by epimerisation clearly dem- 
onstrates the stereo-specificity of the interaction be- 
tween thapsigargin and its binding domain on the ATP- 
ase. 
In conclusion, by studying a number of thapsigargin 
analogues, we have demonstrated that selective modifi- 
cations of this drug result in a stepwise decrease of 
inhibitory potency over a wide range. The high inhib- 
itory potency of the thapsigargin is shown to be criti- 
cally dependent on its coloration, and is consistent 
with the idea of the drug fitting to a cleft involving a 
hydrophobic region of the ATPase. A definite assign- 
ment of the contributions to the binding from the indi- 
vidual groups of the thapsigargin molecule is not possi- 
ble at present. However, a suggestion may be made of 
the relative importance of carboxylic acid substituents 
at C3 and ClO, and a comparatively minor contribution 
from the lactone ring. These observations provide a step 
towards mapping of the thapsigargin-binding domain 
on ER-type Ca2’-ATPases, in an effort to elucidate the 
molecular operation of these pumps. 
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